AgingResearch.NewsJoin free

ArriVent BioPharma

CompanyUnited States

ArriVent BioPharma develops one asset, in phase 3 (firmonertinib in lung cancer). Mostly small molecule acting on EGFR; based in the United States.

1
Asset
Furthest stage
Phase 3
0
Trials
0
Signals

Pipeline

1

  • firmonertinib

    Inhibits epidermal growth factor receptor with exon 20 insertion mutations.

    Phase 3, Small molecule, EGFR, lung cancer, non-small cell lung cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence